SSY Group's Ambroxol Hydrochloride gains bulk drug approval in China

SSY Group Limited has announced its Ambroxol Hydrochloride, an expectorant primarily used for treating respiratory diseases, has received approval for registration from the National Medical Products Administration of China. This approval designates it as a bulk drug for preparations available on the market, marking a key development for the company's product portfolio.

The announcement, dated September 15, 2025, is a voluntary disclosure by the company. It aims to inform shareholders and potential investors about the latest progress in the group's business development. This regulatory achievement is expected to bolster SSY Group's market position within the pharmaceutical sector.

The board of directors oversees the strategic direction of SSY Group. Key executive directors include Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung, and Ms. Qu Wanrong.